Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Imagenetix Inc. (IAGX : OTC)
 
 • Company Description   
Imagenetix, Inc. develops, formulates, and markets over-the-counter, natural-based nutritional supplements and skin care products. It is an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis. Its primary product is Celadrin, a nutritional supplement compound comprised of fatty acid esters that play a role in human and animal joint health; other formulations, including an oral product, a cream, and a pet product; and natural based products for specific health issues, including compounds and formulations. It also develops therapies for the treatment of inflammatory conditions, such as periodontal disease. Its products are proprietary, often supported by scientific studies and are offered through multiple channels of distribution including direct sales to the mass market through retailers, direct marketing companies, medical, health and nutritional professionals, medical newsletters and direct response radio and television.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.00 Daily Weekly Monthly
20 Day Moving Average: shares
Shares Outstanding: (millions)
Market Capitalization: $ (millions)
Beta: 2.55
52 Week High: $0.00
52 Week Low: $0.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week % %
12 Week % %
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
16935 WEST BERNARDO DRIVE SUITE 101
-
SAN DIEGO,CA 92127
USA
ph: 858-323-1688
fax: 858-674-8460
None http://www.imagenetix.net
 
 • General Corporate Information   
Officers
William P. Spencer - President;Chief Executive Officer;Director
Lowell W. Giffhorn - Chief Financial Officer
Barry S. King - Director
Jeffrey G. McGonegal - Director
Robert Burg - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 45247F104
SIC: 2834
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding:
Most Recent Split Date: (:1)
Beta: 2.55
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -
12/31/24 - -
Current Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - -
Quick Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - -
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - -
12/31/24 - -
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©